💊Kyowa Hakko Kirin, anti-Ccr4 humanized antibody acceptance application for European approval of Mogum Lysumab  20171027

By EMA, Pharmaceutical

💊Kyowa Hakko Kirin, anti-Ccr4 humanized antibody acceptance application for European approval of Mogum Lysumab

Kyowa Hakko Kirin is currently developing an anti-CCR4 humanized antibody, Mogamulizumab (development code: KW – 0761), currently under development, by administering cutaneous T – cell lymphoma (CTCL) We will inform you that the application for marketing approval has been accepted from the European Medicines Agency (EMA) and the review has started.

http://www.kyowa-kirin.co.jp/news_releases/2017/pdf/20171027_01.pdf

More from tokioX :

  1. Kyowa Kirin Announces FDA Approval of NOURIANZTM (istradefylline) for Use in Parkinson’s Disease
  2. 💊Fujifilm Kyowa Kirin Biologics与Mylan合作将Humira®生物仿制药商业化（adalimumab）
  3. 💊Sunovion Receives FDA Approval of Supplemental New Drug Application (sNDA) for Use of Latuda (lurasidone HCl) in the Treatment of Bipolar Depression in Pediatric Patients (10 to 17 Years of Age)
  4. 💊Pharma – News Releases
  5. 💊Kyowa Hakko Kirin Announces Discontinuation for Developing ARQ 197 (Tivantinib)
  6. 💊Mitsubishi Tanabe Pharma Corporation] Notice regarding acquisition of manufacturing and sales approval for Rupafin tablets Allergy treatment agent with new mechanism of action shows strong effectiveness with dual action (anti-PAF and antihistamine action)  20170927
  7. PDF]US Food and Drug Administration Grants Breakthrough Therapy Designation for Mogamulizumab for the treatment of Mycosis Fungoides and Sézary Syndrome  Kyowa Hakko Kirin News Releases